Novavax (NVAX) Stock: Gaining Big On Positive Clinical Data


Novavax, Inc. NVAX Stock NewsNovavax, Inc. (NASDAQ: NVAX) is having an incredibly strong start tot he trading session this morning, and for good reason. The company announced its results from a key clinical trial surrounding NanoFlu. Of course, the results were positive, leading to excitement among investors and sending the stock screaming for the top. Today, we’ll talk about the results, what we’re seeing from the stock, and what we’ll be watching for ahead.

NVAX Announces Positive Phase 1/2 Results

As mentioned above, Novavax is having an incredibly strong start to the trading session this morning, after announcing positive clinical results. The results came from the company’s Phase 1/2 clinical trial assessing NanoFlu. NanoFlu is the company’s proprietary recombinant influenza vaccine, a treatment that includes the company’s Matrix-MTM adjuvant.

In a press release issued early this morning, NVAX showed that NanoFlu proved to be a better option than leading licensed egg-based, high-dose influenza vaccines for older adults. In the release, the company said that the vaccine led to significantly higher hemagglutination inhibition (HAI) antibody responses when used against H1N1 and H3N2 strains. The vaccine also showed a comparable HAI response against homologous B/Brisbain Strain.

NVAX also said that the vaccine proved to be well tolerated over the 3-week trial period. As a result of the positive data, the company is expecting to begin a Phase 2 trial surrounding NanoFlu in the third quarter of 2018. In the release, the company said that it would discuss the trial results in greater detail on a conference call following the publication of data.

What We’re Seeing From The Stock 

As investors, one of the first lessons that we learn is that the news moves the market. In this particular case, the news proved to be overwhelmingly positive. After all, what is arguably the most valuable asset in the Novavax pipeline is proving to be effective and safe. Of course, this is leading to excitement among investors. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (7:41), NVAX is trading at $2.69 per share after a gain of $0.52 per share (23.96%) thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on NVAX. In particular, we’re interested in following the story surrounding NanoFlu, as the data continues to be overwhelmingly positive and the vaccine is likely a high-value asset. Think about it, with other, approved vaccines losing efficacy, NanoFlu makes Novavax a takeover target, and if a takeover doesn’t happen, this could be overwhelmingly profitable upon approval. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

For the full CNA Finance report on NVAX, click here!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required


Please enter your comment!
Please enter your name here